MedTrace Logo

The Absorption of Bioactive Berberine in Human

NCT03438292 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2021-01-27

No results posted yet for this study

Summary

Berberine from medicinal plants has therapeutic activities against multiple chronic diseases. But its absorption rate is very low. The objective of this study is to test if adding TPGS or Quillaja extract as an emulsifier enhance the absorption of berberine in human.

Conditions

  • Healthy

Interventions

DIETARY_SUPPLEMENT

Berberine

Two capsules of berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.

DIETARY_SUPPLEMENT

TPGS emulsified berberine

Two capsules of TPGS/Quillaja extract emulsified berberine. Each capsule contains 400 mg berberine. The total amount of berberine throughout is 800 mg.

DIETARY_SUPPLEMENT

Quillaja extract emulsified berberine

Four capsules of Quillaja extract emulsified berberine. Each capsule contains 200 mg berberine. The total amount of berberine throughout is 800 mg.

Sponsors & Collaborators

  • Florida High Tech Corridor Council

    collaborator OTHER

  • Designs for Health

    collaborator INDUSTRY

  • University of Florida

    lead OTHER

Principal Investigators

  • Liwei Gu, PhD · Univerisity of Florida

  • Yavuz Yagiz, PhD · Univerisity of Florida

  • Gary P Wang, MD PhD, FIDSA · Univerisity of Florida

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-09-25
Primary Completion
2020-09-11
Completion
2020-09-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03438292 on ClinicalTrials.gov